Erdal Safak
Research Subjects
Erdal Safak has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Alexander Schirdewan
Charité Campus Benjamin Franklin Medical Clinic II Berlin Germany
1 shared publication- Andreas Busjahn
HealthTwiSt GmbH, Berlin, Germany
1 shared publication Caroline Wilke
1 shared publicationChristian Wende
Department of Cardiology Marien Hospital Papenburg Germany
1 shared publicationDietmar Schmitz
Clinic for Cardiology and Angiology Elisabeth Hospital Essen Germany
1 shared publicationDominik N. Mueller
1 shared publication
Latest Publications
- 30 August 2013
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 37 (1) , 130-1
Clinical efficacy and safety of an implantable cardioverter defibrillator lead with a floating atrial sensing dipole.
- 30 August 2013
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 37 (1) , 130-1
Clinical efficacy and safety of an implantable cardioverter defibrillator lead with a floating atrial sensing dipole.
- 21 May 2013
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 36 (8) , 952-962
Clinical Efficacy and Safety of an Implantable Cardioverter‐Defibrillator Lead with a Floating Atrial Sensing Dipole
Background: The concept of a single‐lead implantable cardioverter‐defibrillator (ICD), with a floating dipole, has been proven safe and functional.Methods and Results: The studied active‐fixation, steroid‐eluting lead (Linoxsmart S DX, BIOTRONIK SE & Co KG, Berlin, Germany) is one French thinner than its predecessor and coated with lubricious SilGlide to improve lead handling. A dedicated ICD device has a self‐adaptive atrial input stage including a fourfold amplifier. The amplification, filtering, and adapted atrial input stage are located in the Lumax 540 VR‐T DX (BIOTRONIK). The Linoxsmart S DX ICD lead delivers only the signal. The lead was evaluated during implantation; at predischarge; and 1‐, 3‐, and 6‐month follow‐up examinations. The primary endpoint (efficacy) was the rate of appropriate atrial sensing tests. The secondary endpoint (safety) was freedom from lead‐related invasive reinterventions. Both safety and efficacy were expected to be significantly higher than 90%.The study enrolled 116 patients at 25 clinical sites. Skin‐to‐skin operation time was 52.4 ± 26.2 minutes. The investigators graded lead insertion as “easy” in 87% of patients. Mean P‐wave amplitudes (preamplified) varied from 5.0 to 6.1 mV in different body positions. Both primary and secondary endpoints were met, as 93.8% (364/388; P = 0.005) of specific sensing tests indicated appropriate atrial sensing, and 94.8% (110/116; P = 0.048) of patients were free from reinterventions (lead dislodgement). Analysis of arrhythmia episodes stored in ICDs and elective 24‐hour Holter electrocardiogram tests raised no concerns about lead functionality.Conclusion: The studied ICD lead with a floating atrial sensing dipole met the predefined safety expectation and demonstrated appropriate atrial sensing performance.
- 21 May 2013
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 36 (8) , 952-962
Clinical Efficacy and Safety of an Implantable Cardioverter‐Defibrillator Lead with a Floating Atrial Sensing Dipole
Background: The concept of a single‐lead implantable cardioverter‐defibrillator (ICD), with a floating dipole, has been proven safe and functional.Methods and Results: The studied active‐fixation, steroid‐eluting lead (Linoxsmart S DX, BIOTRONIK SE & Co KG, Berlin, Germany) is one French thinner than its predecessor and coated with lubricious SilGlide to improve lead handling. A dedicated ICD device has a self‐adaptive atrial input stage including a fourfold amplifier. The amplification, filtering, and adapted atrial input stage are located in the Lumax 540 VR‐T DX (BIOTRONIK). The Linoxsmart S DX ICD lead delivers only the signal. The lead was evaluated during implantation; at predischarge; and 1‐, 3‐, and 6‐month follow‐up examinations. The primary endpoint (efficacy) was the rate of appropriate atrial sensing tests. The secondary endpoint (safety) was freedom from lead‐related invasive reinterventions. Both safety and efficacy were expected to be significantly higher than 90%.The study enrolled 116 patients at 25 clinical sites. Skin‐to‐skin operation time was 52.4 ± 26.2 minutes. The investigators graded lead insertion as “easy” in 87% of patients. Mean P‐wave amplitudes (preamplified) varied from 5.0 to 6.1 mV in different body positions. Both primary and secondary endpoints were met, as 93.8% (364/388; P = 0.005) of specific sensing tests indicated appropriate atrial sensing, and 94.8% (110/116; P = 0.048) of patients were free from reinterventions (lead dislodgement). Analysis of arrhythmia episodes stored in ICDs and elective 24‐hour Holter electrocardiogram tests raised no concerns about lead functionality.Conclusion: The studied ICD lead with a floating atrial sensing dipole met the predefined safety expectation and demonstrated appropriate atrial sensing performance.
- 1 January 2013
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 7 (1) , 24-31
Long-term follow-up of patients with atherosclerotic renal artery disease
- 1 January 2013
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 7 (1) , 24-31
Long-term follow-up of patients with atherosclerotic renal artery disease